Ozempic Maker Sues Spas Selling Variants Of The Drug

Drugmaker Novo Nordisk said it has filed lawsuits targeting medical spas, wellness clinics, and pharmacies, claiming they are improperly selling custom-made versions of its popular medicines for significant weight loss, Janet H. Cho reported for Barron’s Daily.

Photo Insert: Novo Nordisk asked the courts to prevent the spas and clinics from claiming their drugs contain semaglutide, the main ingredient in Ozempic and related drugs.

Novo Nordisk asked the courts to prevent the spas and clinics from claiming their drugs contain semaglutide, the main ingredient in Ozempic and related drugs, and to require them to say their products aren’t affiliated with Novo Nordisk and aren’t approved.

The Food and Drug Administration (FDA) approved Ozempic and Rybelsus to treat Type 2 diabetes, and Wegovy for the management of overweight patients with other conditions such as high blood pressure.

But others who don’t meet the FDA’s criteria want the drugs for weight loss. Novo Nordisk’s monthly price for weight loss drugs is $1,350.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic